Department of Pediatrics, University of Luebeck, University Hospital of Schleswig-Holstein, Lübeck, Germany.
German Center for Infection Research, Lübeck, Germany.
Front Immunol. 2021 Feb 25;11:599104. doi: 10.3389/fimmu.2020.599104. eCollection 2020.
Galectin (gal)-1, -3, and -9 are members of a family of glycan binding proteins that mediate complex interactions between decidual, inflammatory and trophoblast cells modulating several processes during gestation, control of the maternal immune system, and parturition. Their immunomodulatory role in preterm birth and postnatal expression in preterm infants is unknown. We performed a single center prospective study of 170 preterm infants with a gestational age below 35 weeks. Peripheral venous blood samples were collected during the neonatal period and galectin-1, -3, and -9 were determined by ELISA. We noted a strong decline of circulating gal-1 and -3 levels but not gal-9 from birth to day 7 of life. There was an inverse correlation of gal-1 and -3 levels at birth with gestational age. Gal-1 levels were remarkably increased in infants born to amniotic infection syndrome (AIS), which was also observed for gal-9 levels. Infants who developed early-onset sepsis had higher levels of gal-3 at day 1 as compared to unaffected infants. Our observational data imply that galectin-1, -3, and -9 levels are elevated in preterm infants born in an inflammatory milieu such as AIS or EOS. Future studies need to address whether galectins mediate inflammation-induced preterm birth and could therefore be a target for clinical trials.
半乳糖凝集素(Gal)-1、-3 和-9 是糖结合蛋白家族的成员,可介导蜕膜、炎症和滋养层细胞之间的复杂相互作用,调节妊娠期间的几个过程、母体免疫系统的控制和分娩。它们在早产中的免疫调节作用及其在早产儿中的产后表达尚不清楚。我们对 170 名胎龄低于 35 周的早产儿进行了一项单中心前瞻性研究。在新生儿期采集外周静脉血样,并通过 ELISA 测定半乳糖凝集素-1、-3 和-9。我们注意到从出生到生命第 7 天,循环中的 gal-1 和 gal-3 水平呈强下降趋势,但 gal-9 水平没有下降。出生时 gal-1 和 gal-3 水平与胎龄呈负相关。在发生羊膜感染综合征(AIS)的婴儿中,gal-1 和 gal-9 水平显著增加,也观察到 gal-9 水平增加。与未受影响的婴儿相比,在第 1 天患有早发性败血症的婴儿的 gal-3 水平更高。我们的观察数据表明,galectin-1、-3 和-9 水平在 AIS 或 EOS 等炎症环境中出生的早产儿中升高。未来的研究需要解决 galectins 是否介导炎症诱导的早产,因此是否可以成为临床试验的目标。